CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

Key Points

• The aim is to evaluate the impact of CD19-targeting CAR T cells on B-cell immunity in antisynthetase syndrome.
• Directed against B cells and plasmablasts
• Combined with mycophenolate mofetil
• Focus on inducing remission in refractory cases
• Deeply reset B-cell immunity
• Break pathologic B-cell and T-cell responses
• Induce remission in refractory antisynthetase syndrome